The optimal timing to transition from a sphingosine-1-receptor (S1P) modulator to an anti-CD20 agent in certain patients with multiple sclerosis (MS) remains unclear. This Journal Club discussion focuses on an analysis of real-world data and the implications on clinical practice of the association between MS inflammatory activity and the transition period from an S1P modulator to an anti-CD20 agent in patients with MS.
Special Collections
Journal Club
Serum Neurofilament Light Chain in the Prognosis of Disease Activity in Relapsing Multiple Sclerosis
Neurofilament light chain may serve as a prognostic and monitoring biomarker in multiple sclerosis that may be capable of assessing disease activity. This Journal Club discussion highlights recent research published on the prognostic value of serum NfL for on-study disease activity and worsening of disease in patients with relapsing MS.
Background Anti-CD20 therapies rapidly induce a significant depletion of peripheral B cells in patients with multiple sclerosis (MS). As individuals with MS have previously demonstrated impaired responses to COVID-19 vaccines, a study was undertaken to determine whether patients who receive a vaccine prior to initiation of anti-CD20 therapy will demonstrate better responses to a third…
Background Anti-CD20 therapy has been shown to be highly effective at depleting the existing population of immune B cells in patients with multiple sclerosis (MS).1 The goal of therapy is to remove impaired B cells from the immune system, setting the stage for repopulation with a healthier generation of new B cells. Little is known…
